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Abstract 
 Scaffolded DNA origami is a novel DNA-based nanostructure fabrication method that boasts the 
advantages of ease of fabrication, high customizability in terms of geometry and modifications, and low 
cytotoxicity, making it an ideal candidate for biological applications. Several groups have already 
demonstrated its functionality as a drug delivery vehicle, delivering small molecule chemotherapeutics 
and proteins both in vitro and in vivo. However, the field is far from saturated, and many applications of 
these devices remain relatively unexplored. One such avenue within the scope of drug delivery is the 
delivery of antisense therapy, which is showing increasing promise in combating dysregulation of novel 
targets such as microRNA within disease states. Another approach is to expand the functionality of these 
nanostructures in biological systems to include the discovery of new interacting partners with ligands, 
such as microRNA, associated with the nanostructure. The purpose of this work is to expand the field of 
DNA origami into these fields. In the first project, nanostructures functionalized with sequences 
antisense to oncogenic microRNA on the outer surface were successfully fabricated. These structures 
were shown to successfully sequester their target microRNA selectively in solution, and could enter cells 
without any need of modification. Finally, preliminary data was collected suggesting that the amount to 
structures within cells can be quantified, and that these structures retain their functionality and are able 
to affect downstream processes in vitro. In the second project, a process schematic was developed to 
identify and extract ciRS-7, a circular RNA that strongly interacts with miRNA-7. Structures with 
overhangs containing the miDNA-7 sequence and a mechanism for binding to, and being released from 
streptavidin coated beads were successfully synthesized. Each step of the target discovery protocol was 
validated independently in solution.  
This work will hopefully serve as both a basis for optimizing the methods and concepts included within, 
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1.1. DNA Nanotechnology 
Deoxyribonucleic acid, or DNA, is one of the fundamental building blocks of life. It is a polymer 
composed of four unique molecules known as nucleotides: adenine (A), thymine (T), cytosine (C), and 
guanine (G). Each nucleotide itself consists of three basic parts: a 5-carbon deoxyribose sugar ring, a 
phosphate group bonded to the 5’ carbon of the sugar, and one of four nitrogenous bases attached to 
the 1’ carbon of the sugar which gives the nucleotide its identity. The backbone of DNA is formed 
through condensation reactions between the 5’ phosphate of one nucleotide and the 3’ hydroxyl group 
of another. This property gives DNA strands directionality, from the free 5’ phosphate to the free 3’ 
hydroxyl. The nitrogenous bases can be classified into two groups based on chemical structure: the 
pyrimidines (T and C) which consist of a single ring, and the purines (A and G) which consist of two fused 
rings. The bases can form hydrogen bonding interactions with each other, and under standard 
conditions, the nucleotides between two strands of DNA will form Watson-Crick base pairs, i.e. A with T 
and C with G, with high specificity. This base pairing ensures that the greatest number of hydrogen 
bonds are formed while maintaining the isosteric geometry obtained by a purine-pyrimidine interaction. 
The strands are also aligned such that the base pairs are planar, thus maximizing 𝜋 electron interactions 
between subsequent base pairs. This results in the double helical structure of DNA, shown in Figure 1.1, 
where the two strands run anti-parallel to each other, twisting around a central axis, with the bases 
facing towards the center of the helix and forming hydrogen bonds with its Watson-Crick 
complementary base. Within cells, the sequence of nucleotides encodes all the information necessary 
for cellular function, and the specific interactions between complementary bases allow DNA to be 
replicated with high fidelity for the transmission of genetic material to daughter cells. However, the 
same sequence diversity and interaction specificity can be co-opted for the assembly of highly 




Figure 1. 1: Schematic representation (left) and atomistic model (right) of the DNA double helix[1]. 
The foundations of DNA nanotechnology were laid with Nadrian Seeman’s work on 
characterizing immobile DNA junctions and constructing lattices of repeated junctions using sticky end 
adhesions[2]. This method was used to construct 3D structures such as cubes[3], as well as 2D tiled lattices 
and structures with different topologies[4]. However, since structure synthesis involved interactions 
between many short oligonucleotides, the stoichiometry of each strand had to be precisely controlled to 
maintain high yields, and multiple reaction and purification steps were necessary to form complex 
structures. 
These limitations were addressed by Paul Rothemund, who devised an alternative fabrication 
method termed “scaffolded DNA origami”, that consisted of a one-pot reaction between a long single 
stranded DNA (ssDNA) “scaffold” strand, and multiple shorter ssDNA “staple” strands[5]. Rothemund 
demonstrated the fabrication of 2D structures with highly programmable and precise geometries, and 
introduced patterns on the surface of his structures using DNA hairpins. Since then, the field of 
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scaffolded DNA origami has expanded rapidly to include 3D structures with various geometries and 
complex curvatures, and dynamic nanostructures demonstrating a complex range of motion (Figure 1.2). 
 
Figure 1. 2: Survey of DNA origami nanostructures. (A) 2D nanostructures with precise geometry and patterning[5]. (B) 3D 
origami nanostructures with different shapes[6] and (C) curvatures[7]. (D) 3D nanostructures with programmable angular and 
linear motions[8]. (E) Nanostructure with full rotational motion[9]. Scale bars: B,C: 20 nm, D,E: 50 nm. 
 While many applications of DNA origami nanostructures have been developed over the years, of 
particular interest is its function as a drug delivery vehicle in vitro and in vivo. DNA origami provides the 
advantages of high programmability and customizability, ease of fabrication, and inherent lack of 
toxicity, making it an ideal candidate for this role. For example, the clamshell structure in Figure 1.3(A) 
uses an aptamer based “lock and key” mechanism to identify target cells in vitro and selectively deliver 
the molecular payload contained within[10]. Nanostructures have also been used to deliver 
chemotherapeutics both in vitro[11] and in vivo[12], while circumventing drug resistance in vitro. 
Modifications have also been made to DNA origami nanostructures to improve their performance, such 





Figure 1. 3: DNA origami drug delivery vehicles. (A) Dynamic DNA nanostructure capable of delivering payloads in a targeted 
manner[10]. (B) Doxorubicin loaded DNA nanostructures showing efficacy in reducing breast cancer tumors in mice[12]. (C) Lipid 
coated nanoparticles for improved pharmacokinetics and biodistribution[13]. 
 As mentioned earlier, the fabrication of DNA origami nanostructures involves the annealing of 
multiple short “staple” strands to one long “scaffold” strand. The staple strands are piecewise 
complementary to sections of the scaffold, and under annealing conditions the double stranded DNA 
(dsDNA) formed between the scaffold and staple gives it more structure. After this process is repeated 
with ~100 staples, the scaffold adopts its final desired structure. Computer aided design programs have 
been developed to aid in origami design[14], and certain rules have been developed to ensure proper 





Figure 1. 4: Schematic of DNA origami folding. The top panel shows a piecewise complementary staple binding to the scaffold 
and bringing it together. dsDNA within the design are represented as cylinders for simplicity. The bottom panel shows a 
representative staple routing diagram highlighting the structure of staple crossovers. 
 The scaffold strand used is generally derived from the M13mp18 bacteriophage genome whose 
sequence is known, so the sequence of the staples can be generated using complementary base pairing 
rules. Traditionally, to fold nanostructures, the scaffold and staples would be combined in the proper 
ratio in addition to a buffer and divalent cations such as MgCl2 to stabilize charged interactions, heated 
to 65°C, and then cooled slowly over a few days[15]. The initial heating ensures that existing secondary 
structure in the ssDNA have been broken before scaffold-staple interactions begin forming during the 
slow cooling. Recently, Sobczak et al have demonstrated that DNA origami structures can be folded at a 
constant annealing temperature over a period of hours rather than by slowly cooling it over a period of 




1.2. microRNA and circular RNA 
In addition to DNA, cells also contain a second form of nucleic acid, known as ribonucleic acid, or 
RNA. Chemically, RNA has two main differences with DNA: first, the 2’ location on the ribose ring of RNA 
contains a hydroxyl group instead of a hydrogen group, and second, RNA molecules contain the base 
uracil (U) instead of T, which also forms a Watson-Crick base pair with A. However, the structure and 
function of RNA is very different from DNA. Firstly, RNA does not exist solely as a double helix, but can 
form a wide range of secondary and tertiary structures, similar to polypeptides. These conformations 
allow RNA to carry out functions other than information storage, such as target identification and 
reaction catalysis[17].  
The most common forms of RNA are messenger RNA (mRNA), ribosomal RNA (rRNA), and 
transfer RNA (tRNA). mRNA is synthesized by transcribing, or copying the sequence of, DNA. It is then 
spliced to remove introns, or non-coding sequences, and is used to transfer information outside the 
nucleus. The mRNA then encounters the ribosome, which is composed of proteins and rRNA. The 
ribosome translates the message encoded in the mRNA into a sequence of amino acids, thus creating 
the polypeptide chain that is then folded into a functional protein. The amino acids are recognized and 
transferred to the ribosomes by tRNA[17]. However, in recent years, scientists have identified new types 
of RNA that were previously considered to be wasted byproducts of other reactions. One such RNA is 
microRNA (miRNA), short, single stranded, non-coding RNA molecules that were first characterized in 
1993[18], and have since been implicated in a wide variety of diseases[19]. 
miRNA are initially transcribed and modified similar to mRNA, but contain multiple well defined 
secondary structures known as hairpins. These are identified and excised out of the longer strand, 
forming ~70 base hairpin structures that are exported out of the nucleus. In the cytoplasm, the hairpin is 
further processed until a ~22 base dsRNA strand remains. The dsRNA then dissociates and the mature 
single stranded miRNA associates with a protein complex known as the RNA induced silencing complex 
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(RISC). The miRNA is partially complementary to a region on its target mRNA known as the 3’ 
untranslated region (3’UTR), and will bind to the 3’UTR if it comes into contact with the target mRNA. 
The RISC complex can then either act as a nuclease and degrade the mRNA, or can block ribosomes from 
translating the associated mRNA. In both cases, the translation of the mRNA into protein is 
suppressed[20]. Therefore, miRNA play a crucial role in the regulation of mRNA expression in cells. The 
biogenesis of miRNA is shown in Figure 1.5. 
 
Figure 1. 5: Biogenesis of miRNA[17]. 
 The dysregulation of miRNA have been implicated in many diseases, including cancer (Figure 
1.6)[30]. In cancer, miRNA can serve as oncogenes by downregulating tumor suppressor genes, or as 
tumor suppressors by inhibiting oncogenes (Figure 1.6)[30]. Tumor suppressor miRNA are under 




Figure 1. 6: (Top) miRNA associated with the different hallmarks of cancer. (Bottom) Mechanisms of action of both oncogenic 
miRNA and tumor suppressing miRNA[30]. 
For example, miRNA-155 (miR-155) has been shown to be overexpressed in Chronic 
Lymphocytic Leukemia (CLL)[21], and its overexpression has been linked to poor prognosis of patients[22]. 
While a single miRNA may regulate multiple pathways, one possible target for miR-155 is the protein 
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SHIP-1, which regulates the B cell receptor (BCR) pathway in B cell lymphocytes[23]. Another miRNA that 
is overexpressed in CLL[21] and also affects the BCR pathway[24] is miRNA-150 (miR-150). In addition to 
being overexpressed within the cellular environment, these miRNA are also secreted in high relative 
concentrations from the tumor cells into the surrounding environment within extracellular vesicles, or 
membrane bound vessels. These act as a means of communication between the cancer cells and its 
microenvironment, and may play a role in tumor immune response, metastasis, tumorigenesis, 
angiogenesis, drug resistance, or changes in signaling cascades[25]. 
 As mentioned earlier, traditional mRNA production involves splicing the transcription product to 
remove introns. Splicing generally involves one end of an exon, or coding sequence, binding to a 
downstream end of the next exon while removing the intron in between, resulting in a linear product. 
However, in some cases the donor of an exon can bind to an acceptor upstream of itself, thereby 
creating a circular product, in a process known as back splicing (Figure 1.7)[26]. The resulting molecule is 
called a circular RNA (circRNA), and even though it was first identified in the 1990s, its function was then 
unknown. 
 
Figure 1. 7: Schematic showing linear splicing and back splicing to produce circular RNA[27]. 
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 In 2013, Memczak et al discovered one possible function of circRNA as miRNA sponges[28]. 
Specifically, they identified a particular circRNA they termed ciRS-7 that had multiple partially 
complementary binding sites for miR-7 that did not cause RISC formation and circRNA degradation. They 
therefore hypothesized that ciRS-7 can sequester miR-7 from solution, and prevent its regular function 
(Figure 1.8A,B). Alternatively, ciRS-7 also has binding sites for miR-671 that can cause RISC formation 
and ciRS-7 degradation, and so could trigger a release of sequestered miR-7, causing efficient repression 
of miR-7 targets (Figure 1.8C)[29]. However, no circRNA other than the ones reported by Memczak et al 
have shown anti-miRNA activity, so the function of circRNA is still an open question[27]. 
 
Figure 1. 8: Possible mechanisms of ciRS-7 function. (A) ciRS-7 can act as a miR-7 sponge, and prevent miR-7 activity. (B) ciRS-7 




The objectives of this thesis are twofold. The first objective is to expand the repertoire of drug 
delivery candidates for DNA origami to include anti-miRNA therapy due to its potential in treating many 
different forms of cancer. In collaboration with Dr. John C. Byrd of The Ohio State University 
Comprehensive Cancer Center, we aim to develop a nanostructure capable of sequestering the 
overexpressed miR-155 in an in vitro CLL model as a proof of principle.  
The second objective is to develop a methodology of the detection and extraction of 
macromolecules associated with miRNA from cells to identify novel interacting partners of miRNA. As a 




2. Structure Design and Characterization 
2.1. Structure Design 
The nanostructure used in this thesis was adapted from an earlier design by Halley and Lucas et 
al[32] and was termed the “Branch”. The Branch is a rod-shaped 26 helix bundle structure roughly 100 nm 
in length with internal voids, similar to the structure by Halley and Lucas et al (Figure 2.1). The structure 
uses the 7249 base M13mp18 genome as its scaffold. The staple routing and staple sequences were 
generated using the software cadnano[14] and is included as Appendix A. All staples were ordered from 
Eurofins MWG Operon USA (Louisville, KY). 
 
Figure 2. 1: (A) Solid model of the Branch showing dimensions and overhangs. (B) Transmission electron micrograph (TEM) of 
the Branch. (C) Atomic force micrograph of the Branch. Scale bars: 100 nm. 
The key difference between the two designs is the presence of 42 ssDNA “overhangs” patterning 
the outer surface of the Branch. These overhangs were created by extending the staples on the outer 
helices beyond their complementary scaffold sections such that they were exposed to the solutions. The 
arrangement of these overhangs on each face of the Branch is shown in Figure 2.2. The overhangs 
locations were chosen such that they were spaced evenly while ensuring that a 3’ staple end was 




Figure 2. 2: Overhang positions on the Branch. 
 The overhang sequences are completely customizable and they serve as the functional 
component of the structure. The different versions of the Branch fabricated and their overhang 
sequence are listed in Table 2.1. 
Structure Function Overhang sequence (5’->3’) 
No overhang (noOH) Control None 
Scrambled (scr) Control Variable 
Anti-miR-155 (am155) Antisense TTTTTACCCCTATCACGATTAGCATTAA 
Anti-miR-150 (am150) Antisense TTTTTCACTGGTACAAGGGTTGGGAGA 
miDNA-7 (D7) 
DNA presentation TTTTTTGGAAGACTAGTGATTTTGTTGT 
Biotin attachment TTTTTTAACCGCTCTGGTTAACGTGTCTGGGCAAAA 
Table 2. 1: List of different structures by overhang sequence. 
14 
 
 The noOH structure does not contain any overhangs, and is used to control for the effect of 
having overhangs on the structure. The scr structure contains 42 overhangs, each with a unique, random 
sequence, and is used to control for non-specific effects of the overhangs. The sequence of each 
scrambled overhang is included in Appendix A. The final three are functional nanostructures, with the 
sequence marked in red denoting the functional sequence. Both am155 and am150 contain DNA 
sequences that are fully complementary to their respective target miRNA, and are used in the anti-sense 
project. D7 contains two different types of overhangs. 41 out of 42 overhangs contain the DNA analogue 
of the miR-7 sequence for ciRS-7 binding, shown in red in Table 2.1. The red section of the final 
sequence is complementary to an ssDNA strand containing a biotin molecule, and the blue portion of 
the sequence denotes the toehold region for strand displacement. This structure is used in the target 
discovery project and will be elaborated on in Chapter 4. 
2.2. Structure Characterization 
Multiple folding parameters of the structures were characterized to optimize the folding 
process.  Initial characterization was carried out using the noOH structure. The first characterization was 
done by imaging structures using transmission electron microscopy (TEM) and atomic force microscopy 
(AFM). For TEM, structures were deposited on copper mesh grids and stained with uranyl formate for 
imaging. For AFM, structures were adsorbed onto mica surfaces for imaging.  As shown in Figure 2.1B-C, 
the structures look well folded and adopt the expected geometry.  
Next, the optimum salt MgCl2 concentration for structure fabrication was determined. 
Structures were folded at MgCl2 concentrations ranging from 12 mM to 26 mM in a slow cooling ramp[15] 
and then run on a 2% agarose gel in the presence of 11 mM MgCl2 at 70 V for 2 hrs. The resulting bands 
were compared to the scaffold band and imaged using TEM (Figure 2.3A). The structures folded 
successfully over a long range of MgCl2 concentrations (12 – 20 mM) without any aggregation, with 
optimum folding at 18 mM concentration. 
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Next, the ideal annealing temperature for structure folding at a single temperature[16] was 
determined. The mixture of scaffold and staples with 18 mM MgCl2 was heated at 65.0°C for 15 min, and 
then held at a constant temperature between 60.0°C and 40.0°C for 4 hrs, before being cooled down to 
4.0°C. The structures were then run on an agarose gel (Figure 2.3B). The Branch folded over a wide 
range of annealing temperatures starting at 58.8°C. To obtain a finer estimate of the upper limit of 
annealing, the same experiment was conducted with a temperature range of 62.0°C and 58.0°C, which 
showed that the Branch was successfully folded at 59.6°C (Figure 2.3C). Since the Branch seemed to fold 
at any temperature between 59°C and 40°C, a temperature of 54°C was chosen for subsequent folding 
reactions. 
Finally, the folding kinetics of the Branch were determined. After the 65°C melting step, the 
folding reaction at 18 mM MgCl2 was held at 54°C for varying amounts of time between 1 and 120 min, 
before being quenched on ice. The samples were then run on an agarose gel. The nanostructure began 
to fold as early as 1 min into the reaction, with complete folding achieved by 5 min (Figure 2.3D). An 
annealing time of 1 hr was chosen for subsequent folding reactions. 
There were some discrepancies observed between the noOH structure and the structure 
containing overhangs. First, the addition of overhangs of any sequence retarded the bands on the gel. 
This is possibly due to the added weight and resistance imparted by the unstructured ssDNA when 
flowing through the gel. However, none of the folding characteristics studied were impacted by 




Figure 2. 3: Folding characterization of the Branch: (A) salt screen, (B) coarse grain annealing temperature (C) fine grain 
annealing temperature (D) folding time. L: ladder; S: scaffold. 
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3. Antisense Delivery 
3.1. Overview 
As stated earlier, the objective of this project was to design and validate a nanostructure 
capable of sequestering miR-150 and miR-155 within CLL to reverse their oncogenic effects. The am155 
and am150 structures were designed for this purpose. The validation of these structures was broken 
down into three parts: selective sequestration of target miRNA in solution, confirmation and 
quantification of cellular uptake, and sequestration of target miRNA in vitro. 
3.2. Sequestration in Solution 
The selectivity of miRNA sequestration in solution was verified using a fluorescent sequestration 
assay, schematically shown in Figure 3.1. miR-155 conjugated with the ATTO550 fluorophore (fmiR-155), 
and miR-150 conjugated with ATTO647 fluorophore (fmiR-150) (IDT, Coralville, IA) were mixed in 
different proportions in solution. Then, either am155 or am150 structures were incubated with the 
mixture at a final concentration of 1 nM. The structures were incubated in the mixture at 37°C for 2 hrs. 
Afterwards, they were run on an agarose gel and fluorescently imaged using a Typhoon FLA 9500 (GE 
Healthcare and Life Sciences, Chicago, IL). The gel was then stained with SYBR Gold total DNA stain 
(Thermo Fisher Scientific, Waltham, MA) and imaged.  
 
Figure 3. 1: Schematic of miRNA sequestration assay. 
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Since the overhangs on the structures are fully complementary to their target miRNA, we 
hypothesized that only the target miRNA would bind to the structure. Therefore, the structure bands 
would appear on the gel only when the gel is being imaged by the laser that excites the target miRNA 
fluorophore. For example, when the am155 structure is placed in a mixture of fmIR-155 and fmiR150, 
only fmiR-155 should bind to the structure, and the structure bands should only be visible when the gel 
is being imaged using the 532 nm laser. We further hypothesized that, as the relative concentration of 
target miRNA increases, the signal intensity from the structure bands should also increase, until it is 
saturated by miRNA.  
 
Figure 3. 2: miRNA sequestration assay. Each sample well contains both fmiR-155 and fmiR-150 in different ratios of fold excess 
relative to the number of overhangs on the structure, shown at the top. The sample block on the left all contain 1 nM am150 
structures, and the sample block on the right all contain 1 nM am155 structures. The top gel image was taken using the 532 nm 
laser, which excites fmiR-155. The middle gel image was taken using the 640 nm laser, which excites fmiR-150. The bottom gel 
image was taken on a 480 nM light table, and shows the SYBR Gold total DNA stain. 
 Figure 3.2 shows representative results of the miRNA sequestration assay. As expected, when 
the gel was imaged using the green laser, the only signal came from the am155 structures, and when the 
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gel was imaged using the red laser, the only signal came from the am150 structures, suggesting that the 
structures were only able to sequester their respective target miRNA.  
 Interestingly, there is an evident gel shift of the bands as the concentration of the target miRNA 
in the sample increases until a 2 fold excess, after which the gel shift stops. This is possibly due to the 
increased mass of the structure band from the miRNA, which slows the band down. After 2 fold excess, 
the structures are saturated with miRNA, and so adding further miRNA in solution does not affect the 
mass of the structure, and so the gel shift stops. This was not expected, and suggests that the effect of 
sequestration can be observed without necessitating any fluorescence measurements. 
Regardless, the fluorescent intensities of the structure band at different target miRNA 
concentrations were obtained by measuring the pixel intensities of each well in the gel image using a 
MATLAB script (included in Appendix B) and then normalizing by total mass of DNA in the well using the 
SYBR Gold total stain. The intensity values were then plotted against target miRNA fold excess, and are 
shown in Figure 3.3. 
 




 The gel intensity curves follow the same overall pattern as the gel shifts, with intensity 
increasing as fold excess target miRNA increases, until the structures are saturated at around 2 fold 
excess. The am150 curve (Figure 3.3, right) is less smooth compared to both the am155 curve (Figure 
3.3, right) and the gel shift progression. This may be due to errors in the normalization to the SYBR Gold 
total DNA image. Since the concentration of structures was so low, the gels had to be stained in SYBR 
Gold solution for over 45 min, causing the signal to noise ratio to decrease and random bright spots to 
appear on the gel. This made it difficult to accurately quantify the total DNA present in the sample, 
which may have affected the intensity calculations. 
 To ensure that the fluorescent signal in the well was coming from the fluorescent miRNA bound 
to the structure and not from another source, a signal specificity assay was performed (Figure 3.4). 
Solutions were prepared containing a mixture of the same fluorescent and non-fluorescent miRNA 
(cmiR-155 or cmiR-150) (IDT, Coralville, IA), at different ratios. 1 nM of structures were incubated in the 
solution containing its target miRNA for 2 hrs at 37°C. After incubation, the structures were run on a gel, 
and the gel was imaged fluorescently and after staining with SYBR Gold. If the signal is specific to the 
fluorescent miRNA, we hypothesized that as the concentration of non-fluorescent miRNA increases, the 
intensity of the signal from the well should decrease.  
 
Figure 3. 4: Schematic showing methodology for signal specificity assay. 
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 Figure 3.5 shows representative results from a signal specificity assay. As expected, the intensity 
from the bands decreases as the fold excess of non-fluorescent miRNA increases for both structures. 
There is no shift in the bands on this gel, which is expected since any spot not occupied by a fluorescent 
miRNA is expected to be occupied by a non-fluorescent miRNA, so the mass of structures in every well 
should be the same. The densitometric analysis shows that even though the signal was effectively gone 
at 10 fold excess cmiR-150 for am150 structures, there was still a noticeable signal in the am155 sample 
at the same concentration. This could suggest a difference in binding strengths between the fmiR-155 
and cmiR-155. However, more experiments are needed to draw any conclusions. The assay should also 
be performed with 20 fold excess cmiR-155 for a more direct comparison between the two.  
 
Figure 3. 5: Signal specificity assay for (A) am150 structures with fmiR-150 and cmIR-150 and (B) am155 structures with fmiR-
155 and cmiR-155. The top gel shows the fluorescent image taken with (A) 647 nm laser and (B) 532 nm laser. The bottom gel 
shows the SYBR Gold total DNA stain. The graphs show densitometric analyses of the gel band intensities for the two gels. 
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3.3. Cellular Uptake 
Cellular uptake was first assessed qualitatively using fluorescence microscopy experiments using 
the OSU CLL cell line obtained from the Byrd Lab (Figure 3.6). The internal vesicles within these cells 
were stained with a Lysotracker Green dye (Thermo Fisher Scientific, Waltham, MA), which fluoresces 
when excited with 480 nm light. The noOH structures were used for these experiments and were 
stained with TO-PRO-3 dye (Thermo Fisher Scientific, Waltham, MA), which intercalates into DNA and 
fluoresces when excited by a 647 nm laser. The labeled structures were then incubated with the labeled 
cells for varying periods of time, and imaged using a fluorescent microscope (Nikon, Tokyo, Japan).  
It is possible, nominally, to colocalize brightfield images of cells with the fluorescent signal from 
structures to determine whether the structures are within the cells or not. However, since our image is 
only a 2D slice, it is difficult to determine whether the fluorescent signal from the structure arises from 
within the cell or from the surface of the cell. Furthermore, it is believed that DNA origami structures 
enter the cells through an endolysosomal pathway, in which the structure binds to receptors on the cell 
which causes the cell membrane to encapsulate the structure and form an internal vesicle[32]. Therefore, 
if there is colocalization of signal between the nanostructures and the endosomes, then we can 
conclude that the signal is coming from within the cells. Our hypothesis was that we will observe 
colocalization of signals between the Lysotracker Green and TO-PRO-3, suggesting that structures have 
entered the cells, possibly through an endolysosomal pathway. 
 
Figure 3. 6: Schematic of qualitative cellular uptake experiment using a fluorescence microscopy assay. 
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 Experiments were first conducted with 0.5 nM final concentration of nanostructures in each 
well, incubated for 4 hrs. However, very little colocalization was observed, suggesting that either the 
structures were not entering the cells, or there were not enough structures present for a robust 
response. Therefore, the concentration of nanostructures was increased to 10 nM final concentration, 
and the incubation time was increased to 8 hrs. Representative results are shown in Figure 3.7. The 
figure shows colocalization between the Lysotracker signal and the TO-PRO-3 signal, suggesting that 
structures were taken up by the cells. 
 
Figure 3. 7: Fluorescence microscopy images of cellular uptake of DNA origami. ~100,000 cells labeled with Lysotracker were 
seeded in an 8 well imaging plate, and structures labeled with TO-PRO-3 at 10 nM final concentration were incubated with cells 
for 8 hrs. The samples were then imaged with the fluorescent microscope. The white in the far right represents colocalization of 
signal. 
 While this method provides strong visual evidence for cellular uptake, it does not provide an 
easy way to quantify the amount or efficiency of uptake. Therefore, a quantitative polymerase chain 
reaction (qPCR) assay was developed to better quantify our results.  
 PCR (Figure 3.8) is a method by which a target DNA sequence can be amplified exponentially and 
specifically. The basic reaction mix for PCR contains the template, single nucleotides, the polymerase 
enzyme which synthesizes DNA, and primers. The template consists of the target DNA to be amplified 
and possibly off-target DNA as well. Primers are ~20 base length ssDNA that are complementary to the 
ends of the target DNA sequence. The reaction mixture is heated to 95°C to remove any secondary 
structure interactions, and then cooled to an annealing temperature, where the primers can specifically 
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bind to the template DNA. It is then heated up to a temperature where the polymerase enzyme has 
optimal activity. The polymerase then binds to the primer-template complex and extends the primer to 
create the complementary strand to the template. The denaturation-annealing-extension process is 
repeated tens of times. At 100 efficiency, the number of only the dsDNA template will double, thereby 
amplifying the template at an exponential rate until the starting material is used up and the reaction 
saturates.  
 
Figure 3. 8: Schematic for PCR. 
 For quantitative PCR, the reaction is the same, but the mixture also contains at least one 
fluorescent dye as well. In this version, the thermocycler in which the qPCR is being performed can 
excite the sample and take fluorescent measurements, and it does so after every cycle. The dye used 
emits light at different intensities based on whether it is interacting with ssDNA or dsDNA, and so as the 
concentration of dsDNA increases, the fluorescence intensity from the sample increase proportionally. 
Therefore, the method can be used to identify the relative concentration of dsDNA in solution at any 
given cycle number. Since the rate of production of target DNA is proportional to the starting 
concentration of the target DNA, the cycle number at which the target DNA achieves an arbitrary 
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fluorescence value can be used to determine what the starting concentration of target DNA was. To 
quantify the starting amount in absolute terms, a standard curve must first be created by amplifying 
solutions containing known quantities of target DNA and recording the cycle number at which the 
solution reached the set threshold. This curve can then be used to quantify the concentration of an 
unknown sample. Once the amplification is complete, the sample can be slowly heated to 95°C, and the 
fluorescence signal can be monitored over time. If there is only DNA of one length, as is expected from a 
correct amplification, then all the DNA strands should melt at the same temperature, resulting in a 
significant drop in fluorescence intensity at that temperature. If there are multiple intensity drops from 
a sample, then it can be concluded that the amplification was not specific. 
 For our system, the goal was to extract the total DNA from cells incubated with our structure 
and amplify the samples using qPCR to detect and quantify any DNA from our nanostructure, such as the 
scaffold, that may have entered the cell. We hypothesized that, if we amplified total DNA extracts from 
cells incubated with our nanostructures using primers specific for our scaffold sequence, we should 
observe template amplification in our reaction, suggesting that structures were taken up by cells, and 
can quantify the amount of nanostructures taken up using a standard curve. 
 The first step was to generate a standard curve for our scaffold, and we did so by creating a 
serial ten-fold dilution of our scaffold from 109 molecules (1.66 fmol) to 103 molecules (1.66 zmol). 
Forward and reverse primers reported by Okholm et al[33] for the M13mp18 genome were ordered (IDT, 
Coralville, IA). The template and primers were mixed with the Lightcycler 480 SYBR Green Master Mix 
(Roche, Basel, Switzerland) and amplified using the Bio-Rad CFX96 thermocycler (Bio-Rad, Hercules, CA). 




Figure 3. 9: (A) Amplification curves, (B) melt curves, and (C) standard curve for scaffold standards. Each reaction was performed 
in duplicate. 
 The melt curves (Figure 3.9B) for each of the standard showed the same behavior with a melting 
temperature of 83.5°C, suggesting that only the template was amplified. The amplification curves 
(Figure 3.9A) show distinguishable amplification curves for samples down to 105 molecules, suggesting 
that our reaction system can reliably detect down to 105 molecules in solution. Finally, the standard 
curve (Figure 3.9C) shows the expected downward trend with a high R2 value. The efficiency of 
amplification can be calculated using equation 1. 
𝐸 = 10−1/𝑠𝑙𝑜𝑝𝑒     (1) 
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where 100% efficiency means that the number of template molecules doubled at each cycle. The 
efficiency for our reaction was 88.11%, which is lower than recommended, so more optimization must 
be done to achieve higher efficiencies. 
 The next step was to amplify the negative controls, namely the genomic DNA from cells and the 
PCR grade water supplied by the Master Mix. The genomic DNA was extracted from OSU CLL cells using 
the DNEasy Blood and Tissue Kit (Qiagen, Hilden, Germany). In both cases, there should not be any 
scaffold present in the sample, so no amplification was expected. However, as Figure 3.10 shows, in the 
PCR grade water, some DNA was still amplified. Furthermore, the melt curves show a single sharp peak 
with a melting temperature of 83.5°C, suggesting that the DNA amplified is very similar to the target 
DNA.  
 
Figure 3. 10: Amplification curve (left) and melt curve (right) of double distilled water from the laboratory and PCR grade water 
provided in the qPCR kit. 
 This could be due to a few different reasons. The PCR grade water could have been 
contaminated by the items used to prepare the sample, such as tubes or pipette tips. Therefore, 
performing the reactions in sterile conditions could reduce the signal from the PCR sample. Indeed, 
amplification curves of reactions performed with PCR grade water under sterile conditions do show 
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slightly lower starting concentration of DNA, even though there is still amplification (Figure 3.11). 
However, the contamination in the PCR sample is such that it is outside of the detection range of our 
standard curve. Therefore, experiments can still be performed with that level of contamination. 
 
Figure 3. 11: Amplification curve of PCR grade water after sample was prepared under sterile conditions. 
 In terms of the genomic DNA, as Figure 3.12A shows, there seems to be non-specific 
amplification even in the absence of any nanostructure. Unlike the contamination of the PCR grade 
water, this contamination persists even under sterile conditions, suggesting that the primers are at least 
partially complementary to a region in the genomic DNA. The best way to remedy this would be to 
design new primers with the genome of the target cells in mind. However, in the meantime, the loss of 
resolution due to non-specific amplification of genomic DNA can be treated as a lower limit of this 
assay’s detection capability. As Figure 3.12B shows, there seems to be about 4.5x105 molecules of 
nonspecific target in the genomic DNA. Therefore, using the current primers, about 106 molecules of 




Figure 3. 12: (A) Amplification curves of genomic DNA from OSU CLL cells. (B) Standard curve from Figure 3.9 showing the 
starting quantity of nonspecific amplified DNA in genomic sample. 
3.4. Sequestration in vitro 
In the previous sections, the sequestration of miRNA in solution and the cellular entry of 
nanostructures were demonstrated. The next step was to show that structures were still functional 
within the cell by observing some downstream effect of miRNA sequestration in vitro. The was achieved 
using a Luciferase assay.  
Luciferase is an enzyme which, among other things, is responsible for the glow of the fireflies. It 
catalyzes the breakdown of a set of compounds known as luciferin to produce light (Figure 3.13A). In an 
excess of luciferin, therefore, the intensity of light is directly proportional to the concentration of active 
luciferase enzymes in solution. This fact can be used to quantify various expression levels in cells by 
coupling it with the expression levels of luciferase.  
Luciferase assays can also be used to determine the relative miRNA levels in cells using the 
schematic shown in Figure 3.13B. First, the luciferase gene must be modified to include the 3’UTR of a 
gene that is degraded by the miRNA of interest, thus ensuring that the miRNA will interact with the 
luciferase mRNA. Next, the luciferase gene must be transfected into the model cell. The baseline 
luminescence from the system can be obtained by transfecting cells with a copy of the luciferase that 
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does not contain the 3’UTR of the gene of interest. However, when the modified luciferase is 
transfected and expressed by cells, the miRNA will degrade some of the luciferase mRNA, and therefore 
the luminescence intensity will be decreased relative to the control.  
Our assay was based on this same principle. We obtained two types of plasmids from the Byrd 
Lab, one containing the wildtype luciferase gene (-3’UTR), and the other containing the luciferase gene 
modified to include the 3’UTR of SHIP-1, a target of miR-155 (+3’UTR). We originally planned to use OSU 
CLL as our model cells, but due to the low transfection efficiencies associated with OSU CLL, we decided 
to use Human Embryonic Kidney (HEK-293T) cells instead. Cells were grown for 24 hrs in a 24-well 
culture plate before being transfected with the plasmid using Lipofectamine 2000 (Thermo Fisher 
Scientific, Coralville, IA). After 24 hrs, cells were incubated with nanostructure for 8 hrs. Afterwards, the 
Promega Dual Luciferase Assay kit (Madison, WI) was used to lyse and prepare the cell lysates for the 
luminescence readout per protocol. The luminescence intensity readout was recorded using Horiba 
FluoroMax-4 (Irvine, CA). Since bioluminescence was being measured, there was no excitation 
wavelength, and the receptor was set to receive signals from 300 nm to 650 nm.  
Our controls were the luciferase signal intensity from cells transfected with the -3’UTR plasmid 
only, from cells transfected with the +3’UTR plasmid only, and from cells transfected with the +3’UTR 
and incubated with our scrambled control (scr) nanostructure (+3’UTR+scr). Our experimental data were 
from cells transfected with +3’UTR and incubated with the am155 nanostructure (Figure 3.13C). We 
hypothesized that the signal would decrease for the +3’UTR and +3’UTR+scr samples relative to the -
3’UTR sample. However, the signal for the +3’UTR+m155 sample would be higher relative to the +3’UTR 




Figure 3. 13: (A) Chemical reaction showing degradation of luciferin by luciferase. (B) Schematic of luciferase assay used for 
quantifying mIRNA expression levels. (C) Schematic for quantifying miR-155 sequestration by am155 in vitro. 
 Figure 3.13C shows intensities at 527 nm for each sample tested. As expected, the signal 
intensity of the +3’UTR sample is lower than that of the -3’UTR control. Also, as expected, incubating 
cells with am155 nanostructures causes the signal to increase relative to the +3’UTR sample. However, 
there were a lot of discrepancies in the data. In terms of trends, the +3’UTR+scr sample should elicit a 
signal comparable to the +3’UTR control, but is more similar to the experimental sample. Furthermore, 
the decrease in signal of the +3’UTR is very modest, and could possibly fall within error. The graph 
shows data from only one trial, so the variability within the data is still unknown, and no conclusions can 
be drawn. However, the modest decrease in signal could possibly be attributed to the model cell, which 
may not have high expression levels of miR-155. The comparable signals between the am155 and scr 
samples could also be due to some effect that the structure itself, independent of the overhangs, has on 
luciferase expression. Further experiments must be conducted to answer these questions. 
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3.5. Conclusions and Future Work 
 We have successfully fabricated and characterized a nanostructure with ssDNA overhangs on its 
surface fully complementary to either miR-150 or miR-155. We have demonstrated selective 
sequestration of target miRNA in solution by these nanostructures with high efficiency. Furthermore, we 
have qualitatively shown cellular entry of these nanostructures without the need for any further 
modifications. We have established a qPCR protocol to create standard curves for DNA origami scaffold, 
and reduced possible contamination of samples using sterile technique. Finally, we have performed 
preliminary experiments to demonstrate sequestration of miRNA in vitro. 
 Future work will focus on quantifying cellular uptake and replicating the luciferase assay to 
better understand how structures behave in vitro. qPCR will be performed on experimental samples 
using the current protocol to assess its feasibility. New primers that may avoid nonspecific amplification 
of genomic DNA will simultaneously be designed. Finally, intensity analyses can be performed on 
fluorescent microscope images to also quantify the levels of structure uptake in cells. 
 For the luciferase assay, more controls, such as plasmids with a mutated 3’UTR, and native 
plasmids co-incubated with structures, will be developed and implemented to better isolate the effect 
of the functional overhangs on in vitro miRNA levels. In addition, different transfection protocols, such 
as electroporation, will be tested on OSU CLL cells in order to perform the assay in that cell line.  
 In the medium term, our structures must be tested for cytotoxicity, biodistribution, 
pharmacokinetics, and efficacy in vivo. If necessary, further modifications, such as poly-ethylene glycol 
(PEG) coating, 2’O-methyl RNA protection, or cell penetrating peptides may be implemented to improve 
structure performance. In the long term, our structures show great promise as an antisense drug 
delivery vehicle for any disease model with overexpressed miRNA. Furthermore, our work in antisense 
delivery can be synthesized with other areas such as chemotherapeutic delivery and antibody mediated 
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targeting to create a multifunctional drug delivery vehicle that is capable of attacking diseased cells on 
multiple fronts in a targeted manner. 
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4. Target Discovery 
4.1. Overview 
 As stated earlier, the objective of this project was to develop a methodology to identify novel 
interaction partners to nucleic acids, and extract them from a complex mixture for analyses. As a proof 
of principle, we aimed to demonstrate successful isolation of ciRS-7 from cell lysate using a 
nanostructure presenting miD-7 overhangs on its surface. In this chapter, the D7 structure design will be 
elaborated on, the protocol for target discovery and isolation will be presented, and experimental 
results from the validation of each step of the protocol will be discussed. 
4.2. D7 Structure Details 
 Figure 4.1A shows a model of the D7 nanostructure. The miD-7 sequences on the structure 
function similarly to the overhangs on the am150 and am155 structures, in that their task is to bind to 
their complementary strand, which in this case is the anti-miR-7 sequence. However, D7 also contains a 
special overhang (bioAdap) that is not related to any miRNA, but is complementary to a ssDNA strand 
with a biotin attached to it (bioDNA). Furthermore, as seen in Table 4.1, the overhang itself is 36 bases 
long, but the biotinylated strand is only 25 bases long. This is because the function of this overhang is to 
bind to the bioDNA until the bioDNA is displaced by a release strand (disp), which is fully complementary 
to the bioAdap, through toehold mediated strand displacement[34]. 
Strand name Sequence (5’->3’) 
Biotin adapter overhang (bioAdap) TTT TTT AAC CGC TCT GGT TAA CGT GTC TGG GCA AAA 
Biotinylated strand (bioDNA) TTT TGC CCA GAC ACG TTA ACC AGA G 
Release strand (disp) TTT TGC CCA GAC ACG TTA ACC AGA GCG GTT AAA AAA 
Table 4. 1: Sequences of the different componenets of the biotin displacement mechanism. Sections with the same color have 




Figure 4. 1: (A) Model showing the different components of the D7 nanostructure. (B) Schematic showing the steps in toehold 
mediated strand displacement[34]. 
 Toehold mediated strand displacement is a process by which an “invader” strand can displace an 
“incumbent” strand by being complementary to a single stranded domain on the “substrate” strand that 
the incumbent strand is bound to. This is shown in Figure 4.1B. In this case, X is the invader strand, and 
it is complementary to the entirety of the substrate strand, including to the h* domain, whereas the 
incumbent strand is not. The invader strand can bind reversibly to the single stranded “toehold” on the 
substrate, and on occasion, may compete with the incumbent strand in the b domain. The invader and 
incumbent strands may exchange base pairs back and forth, but ultimately the invader strand is more 
favored thermodynamically due to the greater number of base pairs, and will displace the incumbent 
strand[34].  
 In our structure, the 5’ end of the bioAdap remains single stranded when the bioDNA is bound, 
whereas the disp strand is fully complementary to the bioAdap. Therefore, in the presence of disp in 
solution, the bioDNA is expected to be displaced completely by the disp strand. If the nanostructure was 
attached to another component through a streptavidin-biotin interaction, as will be the case, the 
displacement of the bioDNA will result in the release of the structure.  
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4.3. Process Schematic 
 The target discovery and extraction process was broken into three major steps, as shown in 
Figure 4.2. 
 
Figure 4. 2: Process schematic for target discover and extraction using nanostructures. 
 In step 1, the structure with the bioDNA attached (bioD7) is incubated a sample containing the 
target molecule and possible other off target molecules as well. The structure should be able to 
sequester the target molecule selectively from the solution, similar to miRNA sequestration in the 
previous project. In step 2, streptavidin coated magnetic beads are added to the solution and then 
mixed. During mixing, the structures should bind to the bead through streptavidin-biotin interactions. 
The interaction between the protein streptavidin and the small molecule biotin is one of the strongest 
known non-covalent interactions in biology, so the structures should stay attached to the beads. After 
mixing, the beads will be pelleted from the solution by applying a magnetic field to sample. This should 
remove a significant portion of the structures from the solution. In step 3, the supernatant, containing 
all the off-target molecules, will be removed, and the beads will be resuspended in the release buffer 
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containing disp strands and mixed. The disp strands will displace the bioDNA which will remain attached 
to the bead, and the structures will be released from the beads. The beads will then be pelleted and the 
supernatant containing the target molecule bound to the structure will be recovered for analysis. 
4.4. Process Validation 
 Each step of the process was validated in isolation before the whole system was synthesized. 
During the validation, anti-miR-7 sequence conjugated with Cy5 fluorophore (far-7) was used as the 
target molecule for ease of detection. 
 For step 1, the successful incorporation of the bioAdap, the successful binding of the bioDNA, 
and the sequestration of far-7 were verified. The incorporation of bioAdap was tested by incubating D7 
nanostructures with an ssDNA conjugated with ATTO647 fluorophore with the same sequence as the 
bioDNA. D7 structures were incubated with varying concentrations of the fluorescent ssDNA at 37°C for 
2 hrs, then run on a gel, and imaged using the Typhoon gel imager. The results (Figure 4.3A), show that 
the fluorescence intensity does increase as more fluorescent ssDNA is present in the solution. However, 
the signal at a 1:1 ratio of fluorescent ssDNA to bioAdap was very low, suggesting that an excess of 
bioDNA is necessary for complete binding to the structure. 
 
Figure 4. 3: (A) fluorescent gel assay showing successful incorporation of bioAdap into D7. (B) Fluorescent gel assay showing 
successful incorporation of bioDNA into D7. Both images were taken with 647 nm laser. 
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 The incorporation of the bioDNA onto D7 to form bioD7 was also validated using fluorescent gel 
imaging, but with streptavidin conjugated with ATTO647. D7 nanostructures were incubated with 5x 
bioDNA for 2 hrs at 37°C. Afterwards, the nanostructures were purified using poly-ethylene glycol (PEG) 
precipitation following existing protocol[35]. The excess bioAdap had to be removed from solution so that 
the fluorescent streptavidin could only bind to biotin attached to the structures. The structures were 
then incubated with the fluorescent streptavidin at 37°C for 2 hrs, run on a gel, and imaged using the 
Typhoon. The results are shown in Figure 4.3B. The fluorescent signal from the band signifies that 
streptavidin successfully associated with the structure, suggesting that the bioAdap was incorporated 
into the structure. 
 The functionality of the miD-7 overhangs on the structure were tested using the same 
sequestration assay as for am150 and am155, except with only the target strand in solution. Therefore, 
it was expected that the assay would produce the same results. However, in the first few trials, the 
structures in the samples with over equal ratios of far-7 and miD-7 would aggregate in the wells and not 
run at all, thus causing the assay to fail. TEM images of those samples (Figure 4.4A) revealed that the 
structures were binding to each other in a distinct branching pattern, with the tip of one structure 
joined to the side of another. This branching led us to hypothesize that there might be some unwanted 
interactions between the miD-7 overhangs on the surface of the structures and the single stranded 
scaffold loops that were present at the ends of the structure. To test this hypothesis, we identified the 
sequence of the single stranded loops and compared them to the sequence of the D7 overhang 
sequence using MATLAB (code included in Appendix C) to identify the total number of complementary 
bases and number of sequential complementary bases. The analysis showed that there were multiple 
points on the single stranded scaffold loops with up to 6 sequential bases complementary to the 
overhangs, providing locations for possible binding and aggregation. The locations are denoted on the 
scaffold routing in Figure 4.4B. To remedy this situation, the staple routing was changed such that the 
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single stranded scaffold regions that were complementary to the overhangs were removed. The 
updated staple routing is included in Appendix A. 
 
Figure 4. 4: (A) TEM image showing D7 nanostructures bound to one another in the branching pattern. Scale bar is 100 nm. (B) 
Scaffold routing with different regions of high sequential base complementarity highlighted. 
 The new version of D7 was then used to perform the same sequestration assay. The results, 
shown in Figure 4.5, shows that the sequestration assay works as expected, with no unexpected 
aggregation in the wells. This concluded the validation of the components of step 1. 
 
Figure 4. 5: Sequestration assay for far-7. The top gel shows image taken using the 647 nm laser. The bottom gel shows SYBR 
Gold total DNA stain. 
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 In step 2, the binding of the structures to the streptavidin coated magnetic beads was validated. 
The beads were obtained from Spherotech (Lake Forest, IL) and had an average diameter of 4 um. First, 
the functionality of the beads were tested by incubating them with different concentrations of biotin 
conjugated with ATTO550 overnight. To prevent the beads from settling during incubation, the 
incubation was carried out on a rotor. After incubation, the beads were deposited on a glass slide and 
imaged using the fluorescent microscope. As Figure 4.6A shows, the fluorescence intensity around the 
bead increases after incubation in the fluorescent biotin compared to initial. 
 
Figure 4. 6: (A) Fluorescent microscopy image of streptavidin coated magnetic beads imaged using the 532 nm laser before (left) 
and after (right) incubation with fluorescent biotin. (B) Fluorescent microscopy image of streptavidin coated magnetic beads 
imaged using 647 nm laser before (left) and after (right) incubation with far-7 bound bioD7. (C) Concentration of bioD7 in 
supernatant before and after incubation with streptavidin coated magnetic beads. 
 To test the attachment of nanostructures to the beads, bioD7 structures were first incubated 
with far-7 according to sequestration protocol and then purified through PEG precipitation. The 
fluorescent anti-miR-7 served as the signal for structure detection. The concentration of the prepared 
structures was measured on a Nanodrop spectrophotometer (Thermo Fisher Scientific, Coralville, IA) 
before being incubated with the magnetic beads on a rotor overnight. After incubation, the beads were 
pelleted and the concentration of nanostructures were measured again using the Nanodrop. In addition, 
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the beads were also imaged using the fluorescent microscope before and after incubation with the 
nanostructures.  
 As seen in Figure 4.6B, the fluorescence intensity around the magnetic beads increased after the 
incubation with bioD7 with far-7 bound to it, suggesting that the beads can sequester the structures 
from solution. This effect was further quantified using Nanodrop measurements, which shows a drop in 
concentration of the nanostructures in the supernatant after incubation, suggesting that some 
structures are bound to the beads and is therefore not freely available in the solution. However, even 
after an overnight incubation, there was still over 10 nM of structure in the supernatant, suggesting that 
the efficiency of binding to the beads may be low. 
 Finally, in step 3, the dissociation of the nanostructures from the beads through strand 
displacement was tested. First the displacement of bioAdap bound to free streptavidin was studied. To 
accomplish this, bioD7 structures were incubated with ATTO647-conjugated streptavidin at 37°C for 2 
hours, and purified using PEG precipitation. The sample was then incubated with various excess 
concentrations of disp staple before being run on a gel and imaged using the Typhoon. Initially, excesses 
of 5 fold and 10 fold were studied, similar to the other assays. However, no displacement was observed 
at those concentrations. Therefore, to increase the probability of a successful displacement, the excess 
concentration was increased to 50x and 100x, and the incubation temperature was increased to 40°C. 
Under those conditions, strand displacement was observed, as seen in Figure 4.7. Studies have been 
published showing possible interactions between streptavidin and adenine nucleotides[36], and there are 
multiple adenines proximal to the streptavidin in our system, so we hypothesize that the possible 





Figure 4. 7: Fluorescent gel assay showing successful displacement of fluorescent streptavidin associated bioAdap strand. The 
top image was obtained using the 647 nm laser, and the bottom image was obtained using SYBR gold total DNA stain. 
 Lastly, the dissociation of the structures from magnetic beads was tested. This was done by 
analyzing the supernatants obtained after different steps of the process through fluorescent gel imaging 
and total DNA staining. The nanostructures used were bioD7 with far-7 bound as an indicator. The first 
sample (post-seq) was taken after the structures were incubated with the beads. Since it was shown 
that the bead sequestration is not very efficient, we expected some structure to be present in the post-
seq sample. However, this also means that any sample taken after the release solution is added will 
potentially be contaminated with structures that were never attached to the bead. Therefore, a series of 
washes were conducted before the release step, and the supernatant from the washes was analyzed to 
see whether any structure remained. After n washes, the release solution containing disp strands was 
added, and the resulting supernatant was analyzed. We hypothesized that the structure signal would 
fade after the wash, and would recover after addition of the release solution. The schematic of this 




Figure 4. 8: Schematic for the verification of structure release from beads. 
 The results of this experiment is shown in Figure 4.9. 500 μL of 5 nM bioD7 was incubated with 
the magnetic beads on a rotor overnight. Afterwards, the beads were pelleted and the supernatant was 
stored for analysis. The beads were then washed three times using 200 μL of 1x FOB with 18 mM MgCl2, 
the storage buffer for the structures. The supernatant from each wash was collected for analysis. Finally, 
the release solution containing 100 fold excess displacement staples were added to the beads, and the 
beads were shaken and incubated at 40°C for 4 hrs. After the incubation, the beads were pelleted and 




Figure 4. 9: Results of the bead release assay. The top gel shows total DNA stain using SYBR Gold, and the bottom gel shows 
fluorescent gel image using the 647 nm laser. The three post release wells are replicates of the same sample. 
 
 As expected, the post-seq supernatant still contained some structures, showing that the bead 
sequestration is not highly efficient. The fluorescence signal from the band jumped after the first wash, 
which was unexpected. This could be due to the wash volume being lower than the initial volume (200 
μL as opposed to 500 μL), so the remaining structures could have gotten more concentrated. After wash 
2, the structure signal seems to have mostly faded from both the total DNA and fluorescent gels, 
suggesting that washes are successful at removing excess structure. However, the signal seemed to 
return after wash 3. The force of the multiple washes could have dissociated some structures from the 
beads, which could be causing this return in signal. As expected, though, the structure signal did recover 
after the addition of the release solution, both in the total DNA stain and in the fluorescent channel, 
suggesting that the strand displacement reaction did occur. It must be noted, however, that this gel 
represents only one replicate of the experiment, so the discrepancies observed in the gel may be due to 
random error. More trials must be performed to draw conclusions. 
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4.5. Conclusion and Future Work 
 We have successfully designed and fabricated a nanostructure with miD-7 sequences on the 
overhangs, and with a biotin adapter system that can bind to a biotinylated strand and subsequently 
remove it using toehold mediated strand displacement. We have developed a protocol to use these 
structures to select and extract any molecule that interacts with the sequence present on the 
overhangs. As a proof of principle, we have validated all the steps of the protocol individually using 
fluorescently labeled anti-miR-7.  
 Future work in the near term will include synthesizing and testing the entire process in solution, 
testing the sequestration steps using ciRS-7, and in harsher environments such as cell lysate. A model 
system for the proof of principle must also be identified to test the protocol in vitro on naturally 
expressed circRNA. 
 The field of circRNA is very new and in constant flux. The publication by Guo et al[27] challenged 
earlier notions that many circRNA act as miRNA sponges, and that claim still stands. However, most of 
these conclusions are drawn using bioinformatics tools, and an empirical method such as ours may be 
able to discover interactions that do not satisfy the assumptions of these techniques. Therefore, the 
methodology may still be used to detect for circRNA in the future. 
 Perhaps more importantly, the general methodology is not defined by the nature of the target 
molecule. In theory, it should be able to identify and extract any interacting partner to nucleic acids, 
including proteins[31]. Therefore, the focus of this methodology could shift to different classes of 
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Table A 1: Staple sequences for structure fabrication. 
Sequence 
Name Sequence 
Core_01_01 CTG GCA TGG CGA GAA ATG TAA ATC TTA GTC TT 
Core_01_02 AGC TGG CGG GCC AGT GCC TTC CTG TAG CCA GC 
Core_01_03 TGG GAA GGG CGA TCG GAC TCT AGA GGA TCC CC 
Core_01_04 GCC CGA ACT GAT GGC AAT TCA TCA ACA GTA CC 
Core_01_05 ATG CCT GAG TAA TGT GTA GGT AAA CCC CGG TT 
Core_01_06 CAT ATC AAA ATT AAA ATC ATA CAG GGG TAG CT 
Core_01_07 GCG AAA GGC GAT TTA GAG CTT GAC CCA TAT TT 
Core_01_08 CGG CCA ACA CTC GCC AGG GTT TTC TGT GAG CG 
Core_01_09 TTG CCC CAA AAT CGG CAA AAT CCC ACA TTC AA 
Core_01_10 TTT AGC GAA CCT CCC GAC TTG CGG GGG TAT TA 
Core_01_11 AAC GAG TAG TTA CTT AGC CGG AAC TTG TAT CA 
Core_01_12 GTT GGT GTA GAT GGG CTT AAC CAA TAG GAA CGC C 
Core_01_13 ATA CGA GCT CCT GTG TGC CGG AAA CAG TAT CGA AGC 
Core_01_14 GGG TGC CTA GCT CGA ACA GGC TGC ACC GTG CAC CCG 
Core_01_15 AAG ATG ATT AGC GAT AAC ATT CAA AAA TAC ATG GTA 
Core_01_16 ATA GTA TGG TTT GAA ACG CAG AAT TAA CGA GAG AAT 
Core_01_17 AAA GAA CAT GTT TTA AAT ATC GCA AAT GCC TGT AAT 
Core_01_18 GCC GTT TTC AAC ATG TAC AAA TTC TTA CCA GTA ACC 
Core_01_19 GGA TGT CTG GAA GTT TCA TTG AGT AGA TTC AAC GCA 
Core_01_20 ATT GTA ACG TCA AAA ATG AAT AAG AAC GAC AAG CAA 
Core_01_21 AAT GAC AGC GCC ATT CGC CAT TTT CGT AAT ATT TTT GT 
Core_01_22 GAG CCA CCT TGC TTT CTC ACC GTC AAT AAG AGC AAA AGA A 
Core_01_23 TCT GAA TTT ACC GTT CTC ATC GGC ATT TTC GGT CAT AGC C 
Core_01_24 GCC ACC CTA AAG GAG CCT TTA ATT CTA TCT TAA AAC CGA G 
Core_01_25 GCG GAT AAG AGC CGC CGC CAG CAT TGA CAG GAT CAG AGC C 
Core_01_26 TAG CCG AAC GTC CAA TAA GCA AAC AAC GGC GGA TTG ACC G 
Core_01_27 CAC TGA GTT TCG TCA CAG ACA GCC CTC ATA GTA ACA ACT A 
Core_01_28 CCA TCT TTT GGG AAT TAG AGC CAG AGA TAA CCA CGC AGT A 
Core_01_29 TAA TGC GCA TAC CGA AGA GTA GAA GAA CTC AAT ACT ATG G 
Core_01_30 ATC AAT ATT TTT AAA AGT TTG AGT AAC ATT ATG CGG AAT T 
Core_01_31 AAG GCT ATT TTC ATC AAT TCT CCG ATG TGC TGT AAT TAG A 
Core_01_32 TTA AGT TGG GTA AAT CAG CCC TAA TAT GTG AGA TGG AAA C 
Core_01_33 AGA CTT TAC AAA CAA TTT GGA TTA TAC TTC TGT TTC AGG T 
Core_01_34 GAC GCT CAA AAG AGT CCC ACG CTG AGA GCC AGA ACC CTC A 
Core_01_35 TAG CTG TTC GGA AGC ATA AAG TGT AGC GGT CCA CGC TGG T 
Core_01_36 GAT TAG TAT GCT TTC CTC GTT AGA CGC GTA ACC ACC ACA C 
Core_01_37 ACC ATT AGA GAA CCG CCA CCC TCA TTC AGG GAT AGC AAG C 
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Core_01_38 AGG GTG AGA AAG GCC GCC AAA AAC ATT ATG ACG TCA ATA A 
Core_01_39 AGT ACA TAA ATT TTG CAC GTA AAA CAG AAA TAA GAG AAG G 
Core_01_40 GTA TTA ACT CAA CAG TTG AAA GGA TCG TAT TAA ATC CTT T 
Core_01_41 ACG CGA TAG AAC CCT TCT GAC AAC AGT GTG TCC ATC ACG C 
Core_01_42 ATT AGG ATC AGG TCA GAC GAT TGG CCT TGA TAC GGA ACC A 
Core_01_43 CTG GAT AGC AAA GTT ACG ACA ATG AGG CTC CAC AGA ACC G 
Core_01_44 TTG CTT TGG CCG CTA CAG GGC GCG GCG CGG GGC AGG GCG A 
Core_01_45 GAA ACG CAA TTT CAT CAA TCA ATA AGT AAC AAC CCG TCG G 
Core_01_46 AAC AAC GCT ATT TTC ATC GTA GGA ATA TAG AAG GCT TAT C 
Core_01_47 CCG ACA AAT TAT CAT TCC AAG AAC GAG GTT TTG AAG CCT T 
Core_01_48 AAC GGA ACA AAT CTA CGT TAA TAA AAC CGG ATA TTC ATT A 
Core_02_01 CTA ATG CAT TGT GAA TTA CCT TAT TGA CGA GAA ACA CCA G 
Core_02_02 AAC CAA GTC CAG TAA TAG AAA AAG CCT GTT TAA TGT AAA T 
Core_02_03 TGA ACA AGT GTT TAT CGA GGG GGT AAT AGT AAA ATG TAT T 
Core_02_04 ATG GCT TAA AGC GAA CAC GCA TAA CTA AAA CGA AAG AAG A 
Core_02_05 CAC CCA GCT ACA ATT TTT TCC AGA GCC TAA TTA ATG AAA T 
Core_02_06 TTC ATC AAG AGT AAT CCA TAG GCT GGC TGA CCC TTT TTA A 
Core_02_07 TTG GGC GCC AGG GTG GAC TCC AAC GTC AAA GGT AAT GCA G 
Core_02_08 TTC AGC GGA AAG TAC ATG AGG AAG TTT CCA TTA GAA AAC GAG 
Core_02_09 AGA GCC ACC ACC CTC ATC ACG TTG AAA ATC TCA GCG GCA AAA GA 
Core_02_10 CAT TAG CAA GTC AGA GAC ATA AAG GTG GCA ACG CTT AGG TTA AG 
Core_02_11 CGC GAA ACA GTG AGA ACC GCT TTT GCG GGA TCA AAG ATT AAG AG 
Core_02_12 TGG CCC ACT CCA GAC GAC GAC AAT GTA GAA ACC AAT CAA TCT ATT TTG 
Core_02_13 AAG GCG TTT AAT TCT GTA CGT GAA CCA TCA CCC TTA ATG CAC GAG CAC 
Core_02_14 CGC CTC CCG GTT GAG GTA GCG GGG TTT TGC TCT AAC ATC CAC CTT TAA 
Core_02_15 GGA AAC CTA AAA CGA CAA AGG GGG TGG GAA CAT CCA ACA GTT TGA TAA 
Core_02_16 CAT TCC ACC AGT ACA ACG GAA TAG GTG TAT CAG CTA TAT TTA TAA TGC 
Core_02_17 CGA TCT AAA ACC CAT GTA GTA CCG CCA CCC TCA TAC ATT TGC AAC TAA 
Core_02_18 CCA CCC TCC ACC ACC AGT GCC GTC GAG AGG GTG GTG GCA TTT TTG CGG 
Core_02_19 CCC TTA TTA ATG GAA AAA CCT ATT ATT CTG AAA GAT GAA TAA ACA AAA 
Core_02_20 AAA ATC ACT TCA CAA AAG GCT GAG ACT CCT CAA AGA AAT TTG AAT TAC 
Core_02_21 ACA TTA AAC CAG TCA CGA CGT TGT GTC GTG CCA GCT GCA TTT TGC GTA 
Core_02_22 AAA TAT CAC AGC AAA TCA TTC TGG AAA TGG ATA CCT TTT TAT AAA GCC 
Core_02_23 TTG GCA AAA CCG CCT GCC TGA AAG GAA ATA CCA TAA CTA TGT ATC ATA 
Core_02_24 GCA AAC AAA ATA ATT CTA ATG GGA TCT TCG CTA TCG TCA TAA AAG AAG 
Core_02_25 AAA CTA GCC TCA TTT TGC ATC GTA GCA ACT GTA TGC TTT ACG ATA AAA 
Core_02_26 GAT AAT CAT TAA AAT TGA CGA CGA CCA GGC AAC ATA AAT CCA ACA CTA 
Core_02_27 AAC TAA TAC ATT AAA AGA ACT GAT GGC CTT GCA AAT ATA TTG ATA AAT 
Core_02_28 GCT GAA AAT GAT ATA AGT ATA GCC ACT ACA ACG AGC CGC CAC CAG AAC 
Core_02_29 GCC GGA GAG CAA GGC AAA GAA TTA CTA ATA GTA GTA GCA TAG TAC CAG 
Core_02_30 ATT ACC TGA CAA TAA CAT TCC TGA TTA TCA GAG TTA TTA ACT GGT CAG 
Core_02_31 CAT CAA GAA TAC AGT AAT ATA ATC CTG ATT GTT CGA CAA CAT TGA GGA 
Core_02_32 TTA ATT ACT AAT TAA TAT TGA CGG TCC TTA TTC ACA AGA AAT CCC AAT 
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Core_02_33 ATT TCA TTG CGT AGA TAA TAA TGG AAG GGT TAA GGA TTT AGC ACT AAC 
Core_02_34 TTG CTC CTG TCA GGA TAG TTG CGC CCA GAA GGC CGA AGC CAA CGC TAA 
Core_02_35 GAG GTC ATC AAT TCT AGC AAA ATT AAG CAA TAA ACC GTT CAG TCT GGA 
Core_02_36 CTT TTT TAT GAA TAA CGA GGT GAA GGA ATA CCC AAG AAA CTG CCA GTT 
Core_02_37 TGT AGC TCA CTT CAA ATG CAG GGA AAA ATA CGC AGC GAT TAC TGA CCA 
Core_02_38 AGT ACG GTT GCA TCA AGT CAC CCT CTT TTT CAA CGG AGA TGA GGC GCA 
Core_02_39 TTG CGT TGG CAG GTC GTG CGG GCC TAG GTC ACG AGC TTC AGA GCT TAA 
Core_02_40 GCG CGT TTC AGT AAG CTA TAA ACA GTT AAT GCC GGG AGA AAG CAA AAG 
Core_02_41 ACT CAT CTG CGA ATA ATT CGG TCG CTG AGG CTT ATC GCG TCC CCT CAA 
Core_02_42 TGC GTT ATA ATT TAG GCC CTA AAG GGA GCC CCA GCG GGC GAA GGG ATT 
Core_02_43 ATA AAC ACC AAA GAA CAT TAA GAC AAA TTA TTG AGC CAT TTC ATA ATC 
Core_02_44 CGA CCG TGT TTA GTT AAT AAT AAC TTT CTT AAT TAT CAG CAC CGG AAC 
Core_02_45 TAA TGG TTT GTT CAG CGC GAA AAA CCG TCT ATA GAG GCG GTA ATG AAT 
Core_02_46 TTT TGC CAA ACA ATA GCT ATT AAA GAA CGT GGT TTT TCT TTC CAG TCG 
Core_02_47 GCT TTT GCA AAT ATT CGC ACC AAC CCG ATA TAT AAT TTT TGC CTG TAG 
Core_02_48 ACC AAA ATT ACA GGT ATG AGT GTT GTT CCA GTT GAT TGC CCA CAT TAA 
Core_03_01 CCA GAC GAA ACA GTT CAA ACG GGT GTT AAA GGT AGA AAG GTA GCG TAA 
Core_03_02 TCA TAA CCG GAA TAC CTT ATA AAT CAA AAG AAT TGC AGC AAA AGC CTG 
Core_03_03 AGT AAG AGA AAA ATC AAC TAA AGA CAG CAG CGA ACA ACT TCA GAC GTT 
Core_03_04 GTA TAA CGA TAA CAT CAA TAT TAC AAT GGC TAG TCG CTA TAT TTA ACA 
Core_03_05 GGG AGC TAT AAC CGT TCG CTC ATG CGT AAG AAT GAA AAC AGA AAC AAA 
Core_03_06 TTA GAC AGA CCG AGT AAT CGT CTG CCA ACA GAT GAG AAG ATC ATT TCA 
Core_03_07 TTG CTG AAT TCA TTT GAG CTA AAT CGG TTG TAG AGA CAG TTA ATC GTA 
Core_03_08 ACA AAA TAA TTA GTT GAA TCG GCT GTC TTT CCA GGT AAA GAA ATA AGA 
Core_03_09 CGA GCG TCT ATC CTG ACC TAA TTT ACG AGC ATA AAC AAC ATG AAA TAC 
Core_03_10 ACT TTG AAA ACG TAA CAG GAC GTT GGG AAG AAA ACA TTA TAG CGA GAG 
Core_03_11 GAC GGT CAG CTT GCC CGC GAT TTT AAG AAC TGG AGA TTT ACT CGT TTA 
Core_03_12 AAG GAA TTT TGA CCC CTA ATG CCA CTA CGA AGA TTG AAT CTT TAA TTC 
Core_03_13 TAT CAG AGC AAA ATC AGG GAG GGA AGG TAA ATT TTC CCT TAA ATC CAA 
Core_03_14 TGT TAG CAG CTG ATG CAG AAT CCT TAC GTG GCA CAG ACA AAG AGG TGA ACT TCT TT 
Core_03_15 GCG TCT GGC CAA GCT TGC ATG CCT CGC TCA CTG CCC GCT TTT CAC CAG TGA GAC GG 
Core_03_16 TCC AGA ACA CTT GCC TCG AAC CAC CAG CAG AAT AAA ATA TCT TTA GGA GAA GTA TT 
Core_03_17 ATC ATC ATG GAT TCG CCT GAT TGC TGA GTA ACA GTG CCC GGT CAT ACA TGG CTT TT 
Core_03_18 TTA ACG TCA CAT GAA AGT ATT AAG CAA ATA AAT CCT CAT TAA AGC CAG AGC GTT TG 
Core_03_19 TAC CAG TCA AAG CTG CTC ATT CAG TGA ATA AGA TCA TAA GGG AAC CGA ATA CCA AG 
Core_03_20 CCT GGC CCT GAG AGA GTA GCC CGA GAT AGG GTG AAA GAT TCA TCA GTT GCT CAT TA 
Core_03_21 CTG AAC AAA GGC CGG ACA AAG ACA AAA GGG CGG CTT AGA TTG GGT TAT TAC ATT TT 
Core_03_22 AGC CCA ATA CCG ACT TCA TTA AAG GTG AAT TAC TTG CTT CAC TTT TTC TGG TAA TA 
Core_03_23 AGC AAT AGG TAT CGG TAC AGC TTG ATA CCG ATT AGA GAG TTT CTG ACC CAA GGC GA 
Core_03_24 GAA AAG TAC AAA AAA AAC AAC AAC CAT CGC CCC AGA CCG GAC TGC GGA ATT ACG CC 
Core_03_25 AGG TTA TCG ATA AAA CTA TTT TTG CGC CAG CCT CGC AAG ACG GAA TCA TAA TTA CTA AG 
Neighbor_01 CCA TCG ATA GCA GCA CAT CAA TAG 
Neighbor_02 AGA CGG GAA AGA CAC CAC GGA ATA 
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Neighbor_03 ATT TCA ACT TTA ATC AGA TAC ATA CGA GGC AT 
Neighbor_04 CCA GTA ATA AAA GGG AGA AAA ATC TAT AAT CA 
Neighbor_05 CGG CAC CGC TTC TGG TGA AAT TGT AAA CGT TA 
Neighbor_06 GTG AGG CCG AAC GGT ACG CCA GAA AAA GGA AGG GAA GAA A 
Neighbor_07 AAC GGG GTC AGT GCC TTT TGA ATA CGC AGA GGC GAA TTA TGT CA 
Overhang_01 AACATCGCGATTAGAGCCGTGAGAGATCTACA   
Overhang_02 ATATTTTGGAAAAGCCCCAAAAACTAAATGCA   
Overhang_03 ATTGCAACAGGAAAAAGTAGCAATGGCGGTCA   
Overhang_04 CAGGTCATTGCCTGAGTAGCTGATAAATTAAT   
Overhang_05 TAAATCAGATGTCAATCATATGTAGATTCAAA   
Overhang_06 GGGTACCGAATGAGTGAGCTAACTCTTCACCG   
Overhang_07 TGATATTCAAGCCTCAGAGCATAAGGGCGCGA   
Overhang_08 CCAATAGGAGTTTTGTCGTCTTTCTCAACAGT   
Overhang_09 ATTTTTCAATAGATAATACATTTGGAACCTAC   
Overhang_10 ACTTTTGCGGGAGAAGCCTTTATTTTAGTTTG   
Overhang_11 GATGATACGTTTGCCTTTAGCGTCCAATGAAA   
Overhang_12 CCTGTTTACCGTACTCAGGAGGTTTACCGTAA   
Overhang_13 AACGTAGACCGATTGACCAGTAGCACCATTAC   
Overhang_14 TTTTCGAGACCGCACTCATCGAGACGAGGCGT   
Overhang_15 AACGCGCCAAAAATAATATCCCATATCTTACC   
Overhang_16 CGGTATTCAATAGCAGCCTTTACATGAACACC   
Overhang_17 AAATCAAGAACAGCCATATTATTTTTGAGTTA   
Overhang_18 GCAACAGCTTGGAACAAGAGTCCAAACGAACT   
Overhang_19 CCCAAATCAGAGGACAGATGAACGACTAAAAC   
Overhang_20 CCGCCGCGCAAATCAAGTTTTTTGATAAAGTA   
Overhang_21 TGTAGCGGAAGCACTAAATCGGAACAGAGGCA   
Overhang_22 CCAAATAAGAAACGATTTTTTGTTAGCGCTAA   
Overhang_23 TTTTACATCCCCTGCCTATTTCGGGCGCAGTC   
Overhang_24 AAATAACAGGAGGCCGATTACTAGGGCGCTGGCAAG   
Overhang_25 GAAGTCTGCCAGTTTGAGGGCGCATTAACATGGTCA   
Overhang_26 TCCGATATAAAAACCAGCGCAACGTCACAGACTGTA   
Overhang_27 ATACGTGTACAGACCAGGCGTTGACAAGATAAGTCC   
Overhang_28 AGAATGGGTCGAGGTGCCGTATCACGCTGATCAGAGC   
Overhang_29 ATCAAAGAGAATCGATGAACGGCAAATCACCATCAATA   
Overhang_30 AACGCTCAGAGAATCGGGGGAAAG   
Overhang_31 TCGCCTGATAAATTGTGTCGAAAT   
Overhang_32 TGGTTCCGGCAGGCGACACACAAC   
Overhang_33 CAGAAGGACATTTTGCTGAACCTC   
Overhang_34 AGAATCAAAGGAGTGTACTGGTAA   
Overhang_35 AGTAAATGCCCTCATTGAACCGCC   
Overhang_36 AAAATTCATGAATTTATCAAAATC   
Overhang_37 CTGCGAACCCATATAACAGTTGAT   
Overhang_38 TGCTCCATGTAAATTGGGCTTGAG   
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Overhang_39 AACATAAACAAATCAGATCATTAC   
Overhang_40 CAGAAGCAGCCTCAGGAAGATCGCACTCCAGC   
Overhang_41 AGGATAAAATATATTTAGGAAGATTGTATAAG   
Overhang_42 GAGAGACTTATTTACATTGGCAGATTCACCAG   
Overhang_43 TACAGAGGCTTTGAGGGGTCTTTACCCTGACT   
Overhang_44 TTTTGCTAAAAGACAGCATCGGAACGAGGGTA   
 

































































% Halley megafold paper 
% plotting and quantifying gel images rapid fold and kinetics 
  
clc, clear all, close all 
  
gel_gray = imread('20150806 Br R7 overhang incorporation test-532nm.tif'); 
gel_double = im2double(gel_gray); 
  
rect0 = [135.5100    0.5100  488.9800  103.9800]; 
h1 = figure(1); 
imshow(gel_double) 
xlabel('crop image to structure lanes','FontSize',20,'Fontweight','bold') 
gel_crop_rect = imrect(gca, rect0); 
pause 
rect = gel_crop_rect.getPosition; 
xpos = rect(1); 
ypos = rect(2); 
box_width = rect(3); 
box_height = rect(4); 
  
gel_crop_im = gel_double(ypos:(ypos+box_height),xpos:(xpos+box_width)); 
  
%% background subtraction 
figure(2) 
contour(gel_crop_im,'Fill','on') 
set(gcf,'Position',[25 25 400 400]) 
xlabel('select 30 points for background','FontSize',20,'Fontweight','bold') 
  
fit_length = 20; 
x_fit = zeros(fit_length,1); 
y_fit = zeros(fit_length,1); 
z_fit = zeros(fit_length,1); 
  
% uncomment to pick points from image 
for i=1:30 
    [x_pt, y_pt] = ginput(1); 
    x_fit(i) = round(x_pt); 
    y_fit(i) = round(y_pt); 
    z_fit(i) = gel_crop_im(y_fit(i),x_fit(i)); 
    hold on 
    plot(x_fit(i),y_fit(i),'kx','Linewidth',2,'MarkerSize',10) 
end 
  
% coodinates for horse screen 2 
% x_fit = [3 74 158 255 361 425 487 8 128 246 365 485 65 126 251 372 480 5 125 249 372 
482 485 249 367 65 10 7 320 427]'; 
% y_fit = [97 97 100 101 102 101 101 80 79 80 80 82 58 57 57 59 61 38 40 40 41 40 24 
25 25 25 22 11 15 15]'; 
% hold on 
% plot(x_fit,y_fit,'kx','Linewidth',2,'MarkerSize',10) 
% z_fit = [0.1176 0.1373 0.1569 0.1686 0.1529 0.1255 0.1020 0.1216 0.1529 0.1647 
0.1490 0.1137 0.1333 0.1451 0.1333 0.1216 0.1451 0.1059 0.1294 0.1176 0.1020 0.0980 
0.0824 0.1098 0.0941 0.1176 0.1098 0.0980 0.0980 0.0863]'; 
  
poly3 = polyfitn([x_fit y_fit],z_fit,3); 
[r, c] = size(gel_crop_im); 
  
[x_grid, y_grid] = meshgrid(1:c,1:r); 
x_bg1 = reshape(x_grid,r*c,1); 
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y_bg1 = reshape(y_grid,r*c,1); 
z_bg1 = polyvaln(poly3,[x_bg1 y_bg1]); 
  
x_bg = reshape(x_bg1,r,c); 
y_bg = reshape(y_bg1,r,c); 




view([0 1 0.5]) 
set(gcf,'Position',[450 25 400 400]) 
x_lim = get(gca,'Xlim'); 
y_lim = get(gca,'Ylim'); 
z_lim = get(gca,'Zlim'); 





view([0 1 0.5]) 









view([0 1 0.5]) 
set(gcf,'Position',[1300 25 400 400]) 
xlabel('Post background subtration','FontSize',20,'Fontweight','bold') 
  
%% Thesholding and rotating image 
  
% threshold image 
z_norm = reshape(gel_norm,1,r*c); 
im_avg = mean(z_norm); 
im_std = std(z_norm); 
im_thrsh = zeros(size(gel_norm)); 









xlabel('Median Filtered threshold','FontSize',20,'Fontweight','bold') 
  
% rotating image if necessary 
  
theta_deg = -5:0.2:5; 
col_num_zero = 1000*ones(size(theta_deg)); 
max_col_sum = zeros(size(theta_deg)); 
  
% uncomment below to do automatic rotation 
% for n=1:length(theta_deg) 
%     gel_rot_thrsh = imrotate(im_thrsh2,theta_deg(n),'bicubic'); 
% %     figure(8) 
% %     imshow(gel_rot_thrsh) 
%     col_sum = sum(gel_rot_thrsh,1); 
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%     max_col_sum(n) = max(col_sum); 
% %     figure(9) 
% %     plot(1:length(col_sum),col_sum) 
%     col_nonzeros = nonzeros(col_sum); 
%     col_num_zero(n) = length(col_sum)-length(col_nonzeros); 
% %     keyboard 
% end 
  
% [max_col, max_n] = max(col_num_zero); 
% theta_rot = theta_deg(max_n); 
  
% uncomment below to do manual rotation 




xlabel('Set line for rotation','FontSize',20,'Fontweight','bold') 
rot_line = imline(gca); 
pause 
rot_pos = rot_line.getPosition; 
rot_x1 = rot_pos(1,1); 
rot_x2 = rot_pos(2,1); 
rot_y1 = rot_pos(1,2); 
rot_y2 = rot_pos(2,2); 




gel_rot_thrsh = imrotate(im_thrsh2,theta_rot,'bicubic'); 
[r1 c1] = size(gel_rot_thrsh); 
  
  
%% increasing display resolution by interpolation 
gel_rot = imrotate(gel_norm,theta_rot,'bicubic'); 





% view([1 0 4]) 
view([0 1 20]) 




%% Detect lane edges 
N = 7; % number of bands 
band_left = zeros(1,N); 




% k=1; % if k=1 looking for left edge (if k=2 looking for right edge) 
%  
% for n=1:c1 
%     col_sum_n = sum(gel_rot_thrsh(:,n)); 
%     if k==1 % looking for left edge 
%         if col_sum_n ~= 0 
%             band_left(k_left)=n-1; 
%             k_left=k_left+1; 
%             k=2; 
%         end 
%     else 
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%         if col_sum_n==0 
%             band_right(k_right)=n; 
%             k_right=k_right+1; 
%             k=1; 
%         end 
%     end 
% end 
  
h10 = figure(10); 
h10_axes = axes; 
imshow(gel_rot), hold on 
colormap jet 




%% Removing negative intensity from wells 
  
% Set a rectangle to define new background. Wells will be removed by 
% eliminating any pixels with intensity less than then minimum of the 
% background. 
xlabel('Set rectangle for background','FontSize',20,'Fontweight','bold') 
gel_back_rect = imrect(gca); % selecting rectangle of background on background 
subtracted image 
back_rect = gel_back_rect.getPosition; 
xpos_bg = back_rect(1); 
ypos_bg = back_rect(2); 
box_width_bg = back_rect(3); 





% Now plot lane edges after selectingbackground 
% for i=1:N 
%     plot(band_left(i)*ones(1,r1),1:r1,'r','linewidth',2) 
%     plot(band_right(i)*ones(1,r1),1:r1,'b','linewidth',2) 
% end 
  
v_line = imline(h10_axes); 
v_pos = v_line.getPosition; 
  
for i=1:N 
    xlabel('Set left edge','FontSize',20,'Fontweight','bold') 
    v_line1 = imline(h10_axes, v_pos); 
    pause 
    band_left_pos = v_line1.getPosition; 
    band_left(i) = band_left_pos(1); 
%     v_pos(1,:) = v_pos(1,:)+50; 
%     v_pos(2,:) = v_pos(2,:)+50; 
  
    xlabel('Set right edge','FontSize',20,'Fontweight','bold') 
    v_line2 = imline(h10_axes, v_pos); 
    pause 
    band_right_pos = v_line2.getPosition; 
    band_right(i) = band_right_pos(1); 
%     v_pos(1,:) = v_pos(1,:)+20; 
%     v_pos(2,:) = v_pos(2,:)+20; 
end 
  
min_bg = min(min(im_back_rect)); 








% view([1 0 4]) 
view([0 1 20]) 
set(gcf,'Position',[2225 25 400 400]) 
set(gca,'XDir','reverse') 
xlabel('Neg. intensity of wells removed','FontSize',20,'Fontweight','bold') 
  
%% Calculating amount in folded structure band 
  
% summing total intensity for each lane 
% tot_band_int = zeros(1,N); 
% for i=1:N 
%     tot_band_int(i) = sum(sum(gel_rot(:,band_left(i):band_right(i)))); 
% end 
  
% Defining section for folded structure band 
figure(10) 
xlabel('Set top of folded band region','FontSize',20,'Fontweight','bold') 
h_line1 = imline(h10_axes); 
pause 
pos_line1 = h_line1.getPosition; 
c1 = polyfit(pos_line1(:,1)',pos_line1(:,2)',1); 
  
pos_line2 = pos_line1; 
pos_line2(:,2) = pos_line2(:,2)+14; 
xlabel('Set bottom of folded band region','FontSize',20,'Fontweight','bold') 
h_line2 = imline(h10_axes,pos_line2); 
pause 
pos_line2 = h_line2.getPosition; 
c2 = polyfit(pos_line2(:,1)',pos_line2(:,2)',1); 
%% 
% summing intensity in folded structure band for each lane 
band_sum = ones(1,N); 
for i=1:N 
    band_im = gel_rot(:,(band_left(i)):(band_right(i))); 
    band_width = band_right(i)-band_left(i); 
    figure(12),clf 
    subplot(1,2,1) 
    imshow(band_im) 
    set(gcf,'Position',[1800 600 100 300]) 
    x1_top = 1; 
    y1_top = c1(1)*band_left(i)+c1(2); 
    x2_top = band_right(i)-band_left(i)+1; 
    y2_top = c1(1)*band_right(i)+c1(2); 
    x1_bot = 1; 
    y1_bot = c2(1)*band_left(i)+c2(2); 
    x2_bot = band_right(i)-band_left(i)+1; 
    y2_bot = c2(1)*band_right(i)+c2(2); 
%     hold on 
%     plot([x1_top x2_top x2_bot x1_bot x1_top],[y1_top y2_top y2_bot y1_bot 
y1_top],'r--') 
%     pause 
    poly_band = impoly(gca,[x1_top, y1_top; x2_top, y2_top; x2_bot, y2_bot; x1_bot, 
y1_bot],'Closed',1); 
    band_mask = poly_band.createMask; 
    band_sum_im = band_im.*band_mask; 






lane = 1:N; 
Temp = [0 .25 .5 1 2.5 5 10]; 
% Temp = fliplr([40 41.7 44.4 47.8 52.5 56 58.4 60]); 
% Temp = fliplr([48 48.4 48.9 49.6 50.5 51.2 51.7 52]); % LPP fine screen 
% Temp = fliplr([50.0 50.4 50.9 51.6 52.5  53.2 53.7 54.0]); % 18hb fine screen 
% Temp = fliplr([58 58.4 58.9 59.6 60.5 61.2 61.7 62]); % Horse fine screen 
% band_sum_norm = band_sum; 
  
figure(13),hold on, box on 
set(gcf,'Color',[1 1 1]) 
set(gca,'FontSize',30,'Xlim',[min(Temp) max(Temp)],'Ylim',[0 320]) 
plot(Temp,band_sum,'k','linewidth',2) 





% figure(14),hold on, box on 
% set(gcf,'Color',[1 1 1]) 
% set(gca,'FontSize',30,'Xlim',[min(Temp) max(Temp)],'Xdir','reverse','Ylim',[-0.05 
1]) 
% plot(Temp,band_sum_norm,'k','linewidth',2) 
% xlabel('Annealing Temperature (^oC)','FontSize',30) 
% ylabel('Lane Normalized Intensity','FontSize',30) 
  
filename = '20150806 Br R7 overhang incorporation test-532nm.txt'; 











% This program takes a specific input sequence entered as 'seq' and tests 
% it agains a list of staples and/or ssDNA ('stapletext') to find the maximum number 
of 
% total base pairs and the maximum number of sequential base pairs.  These 
% can then be checked in IDT to test the stability. 
  






% good sequence for FRET box 'CGGGAAGACACTAGG' 
  
NN=length(seq); % Length of sequence 
showall=0; 
  
    input_seq=seq; 
     
    % ComplimentaryStapleCheck.txt should list staple sequences in rows  
    stapletext = importdata('ciRS-7 sequence.txt','%s'); 
     
    max_comp_tot=zeros(1,length(stapletext)); 
    max_seq_comp=zeros(1,length(stapletext)); 
    for QQ = 1:length(stapletext) % check each staple in file 
  
        test_staple=stapletext{QQ}; 
  
        % Compute Reverse Compliment 
        staple_comp=test_staple; 
        staple_comp(test_staple=='A')='U'; 
        staple_comp(test_staple=='U')='A'; 
        staple_comp(test_staple=='G')='C'; 
        staple_comp(test_staple=='C')='G'; 
        staple_Rcomp=fliplr(staple_comp); 
         
%         sprintf('\n%s\n%s\n',rand_seq,staple_Rcomp) 
         
        % Keep rand_seq fixed and run staple reverse complement across the 
        % rand_seq to check for complementary base pairs 
         
        l_stap=length(test_staple); 
        l_rand=length(input_seq); 
         
        comp_tot=zeros(1,(l_stap+l_rand-1)); 
        seq_comp=zeros(1,(l_stap+l_rand-1)); 
        for i=1:(l_stap+l_rand-1) 
            b_stap1=max([(l_stap-i+1),1]); % first staple base in test range 
            b_stap2=min([l_stap,(l_rand+l_stap-i)]); % second staple base in test 
range 
            b_rand1=max([1,(i-l_stap+1)]); % first rand_seq base in test range 
            b_rand2=min([l_rand,i]); % second rand_seq base in test range 
             
            % printing out sequences for visualizing comparison 
%             clc 
%             stap_text=strcat(sprintf(strcat('''%',num2str(i),'s'''),' 
'),staple_Rcomp); 




%             sprintf('\n%s\n%s\n',stap_text,rand_text) 
             
            % comparing sequences 
            rand_test=input_seq(b_rand1:b_rand2); 
            stap_test=staple_Rcomp(b_stap1:b_stap2); 
            comp_tot(i)=sum(rand_test==stap_test); 
            sum_seq_comp=zeros(size(rand_test)); 
             
            % calculating maximum sequential number of complementary base pairs 
            for j=1:length(rand_test) 
                if j==1 
                    if rand_test(j)==stap_test(j) 
                        sum_seq_comp(j)=1; 
                    end 
                else 
                    if rand_test(j)==stap_test(j) 
                        sum_seq_comp(j)=sum_seq_comp(j-1)+1; 
                    else 
                        sum_seq_comp(j)=0; 
                    end 
                end 
            end 
            seq_comp(i)=max(sum_seq_comp); 
%             pause(0.01) 
        end 
         
        % maximum total complementary base pairs for the staple/rand_seq combination 
        max_comp_tot(QQ)=max(comp_tot); 
        i_mct=find(max_comp_tot(QQ)==comp_tot); 
        % maximum sequential complementary base pairs for the staple/rand_seq 
combination 
        max_seq_comp(QQ)=max(seq_comp); 
        i_msc=find(max_seq_comp(QQ)==seq_comp); 
         
        if showall 
            fprintf('\n\nStaple: %s\nRandon sequence: %s\n',test_staple,input_seq) 
         
            for i=1:length(i_mct) 
                b_mct_stap1=max([(l_stap-i_mct(i)+1),1]); 
                b_mct_stap2=min([l_stap,(l_rand+l_stap-i_mct(i))]); 
                b_mct_rand1=max([1,(i_mct(i)-l_stap+1)]); 
                b_mct_rand2=min([l_rand,i_mct(i)]); 
                rand_test=input_seq(b_mct_rand1:b_mct_rand2); 
                stap_test=staple_Rcomp(b_mct_stap1:b_mct_stap2); 
                n_blanks=max([l_stap,i_mct(i)]); 
                base_match=rand_test; 
                base_match(stap_test==rand_test)='|'; 
                base_match(stap_test~=rand_test)=' '; 
                stapRC_text=strcat(sprintf(strcat('''%',num2str(i_mct(i)),'s'''),' 
'),staple_Rcomp); 
                stap_text=strcat(sprintf(strcat('''%',num2str(i_mct(i)),'s'''),' 
'),fliplr(test_staple)); 
                bp_text=strcat(sprintf(strcat('''%',num2str(n_blanks),'s'''),' 
'),base_match); 
                rand_text=strcat(sprintf(strcat('''%',num2str(l_stap),'s'''),' 
'),input_seq); 
                fprintf('\nMax total complementary base pairs is: 
%s\n\n%s\n%s\n%s\n%s\n',num2str(max_comp_tot(QQ)),stap_text,stapRC_text,bp_text,rand_t
ext) 
%                 pause 
            end 
         
            for i=1:length(i_msc) 
64 
 
                b_msc_stap1=max([(l_stap-i_msc(i)+1),1]); 
                b_msc_stap2=min([l_stap,(l_rand+l_stap-i_msc(i))]); 
                b_msc_rand1=max([1,(i_msc(i)-l_stap+1)]); 
                b_msc_rand2=min([l_rand,i_msc(i)]); 
                rand_test=input_seq(b_msc_rand1:b_msc_rand2); 
                stap_test=staple_Rcomp(b_msc_stap1:b_msc_stap2); 
                n_blanks=max([l_stap,i_msc(i)]); 
                base_match=rand_test; 
                base_match(stap_test==rand_test)='|'; 
                base_match(stap_test~=rand_test)=' '; 
                stapRC_text=strcat(sprintf(strcat('''%',num2str(i_msc(i)),'s'''),' 
'),staple_Rcomp); 
                stap_text=strcat(sprintf(strcat('''%',num2str(i_mct(i)),'s'''),' 
'),fliplr(test_staple)); 
                bp_text=strcat(sprintf(strcat('''%',num2str(n_blanks),'s'''),' 
'),base_match); 
                rand_text=strcat(sprintf(strcat('''%',num2str(l_stap),'s'''),' 
'),input_seq); 
                fprintf('\nMax sequential complementary base pairs is: 
%s\n\n%s\n%s\n%s\n%s\n',num2str(max_seq_comp(QQ)),stap_text,stapRC_text,bp_text,rand_t
ext) 
%                 pause 
            end 
        end 
         
%         pause 
    end 
    clear comp_tot 
     
    max_all_staple_comp_tot=max(max_comp_tot); 
    i_mast=find(max_all_staple_comp_tot==max_comp_tot); 
    max_all_staple_seq_comp=max(max_seq_comp); 
    i_mass=find(max_all_staple_seq_comp==max_seq_comp); 
     
    %% Repeating loop for the staples that yield maximum number of complmentary base 
pairs 
     
    fprintf('\nMax total complementary base pairs is: %i\n',max_all_staple_comp_tot) 
    for nn=1:length(i_mast) 
        test_staple=stapletext{i_mast(nn)}; 
  
        % Compute Reverse Compliment 
        staple_comp=test_staple; 
        staple_comp(test_staple=='A')='U'; 
        staple_comp(test_staple=='U')='A'; 
        staple_comp(test_staple=='G')='C'; 
        staple_comp(test_staple=='C')='G'; 
        staple_Rcomp=fliplr(staple_comp); 
     
%         sprintf('\n%s\n%s\n',rand_seq,staple_Rcomp) 
         
        % Keep rand_seq fixed and run staple reverse complement across the 
        % rand_seq to check for complementary base pairs 
         
        l_stap=length(test_staple); 
        l_rand=length(input_seq); 
         
        comp_tot=zeros(1,(l_stap+l_rand-1)); 
        seq_comp=zeros(1,(l_stap+l_rand-1)); 
        for i=1:(l_stap+l_rand-1) 
            b_stap1=max([(l_stap-i+1),1]); % first staple base in test range 




            b_rand1=max([1,(i-l_stap+1)]); % first rand_seq base in test range 
            b_rand2=min([l_rand,i]); % second rand_seq base in test range 
             
            % comparing sequences 
            rand_test=input_seq(b_rand1:b_rand2); 
            stap_test=staple_Rcomp(b_stap1:b_stap2); 
            comp_tot(i)=sum(rand_test==stap_test); 
         
%             pause(0.01) 
        end 
         
        % maximum total complementary base pairs for the staple/rand_seq combination 
        max_comp_tot1=max(comp_tot); 
        i_mct1=find(max_comp_tot1==comp_tot); 
         
        fprintf('\n\nStaple #%i: %s\nTest sequence: 
%s\n',i_mast(nn),test_staple,input_seq) 
         
        for i=1:length(i_mct1) 
            b_mct_stap1=max([(l_stap-i_mct1(i)+1),1]); 
            b_mct_stap2=min([l_stap,(l_rand+l_stap-i_mct1(i))]); 
            b_mct_rand1=max([1,(i_mct1(i)-l_stap+1)]); 
            b_mct_rand2=min([l_rand,i_mct1(i)]); 
            rand_test=input_seq(b_mct_rand1:b_mct_rand2); 
            stap_test=staple_Rcomp(b_mct_stap1:b_mct_stap2); 
            n_blanks=max([l_stap,i_mct1(i)]); 
            base_match=rand_test; 
            base_match(stap_test==rand_test)='|'; 
            base_match(stap_test~=rand_test)=' '; 
            stapRC_text=strcat(sprintf(strcat('''%',num2str(i_mct1(i)),'s'''),' 
'),staple_Rcomp); 
            stap_text=strcat(sprintf(strcat('''%',num2str(i_mct1(i)),'s'''),' 
'),fliplr(test_staple)); 
            bp_text=strcat(sprintf(strcat('''%',num2str(n_blanks),'s'''),' 
'),base_match); 
            rand_text=strcat(sprintf(strcat('''%',num2str(l_stap),'s'''),' 
'),input_seq); 
            fprintf('\n%s\n%s\n%s\n%s\n',stap_text,stapRC_text,bp_text,rand_text) 
%             pause 
        end 
    end   
     
    %% Repeating loop for staples that yield maximum number of sequential 
complementary bases 
     
    fprintf('\nMax sequential complementary base pairs is: 
%i\n',max_all_staple_seq_comp) 
    for nn=1:length(i_mass) 
        test_staple=stapletext{i_mass(nn)}; 
  
        % Compute Reverse Compliment 
        staple_comp=test_staple; 
        staple_comp(test_staple=='A')='U'; 
        staple_comp(test_staple=='U')='A'; 
        staple_comp(test_staple=='G')='C'; 
        staple_comp(test_staple=='C')='G'; 
        staple_Rcomp=fliplr(staple_comp); 
     
%         sprintf('\n%s\n%s\n',rand_seq,staple_Rcomp) 
         
        % Keep rand_seq fixed and run staple reverse complement across the 
        % rand_seq to check for complementary base pairs 
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        l_stap=length(test_staple); 
        l_rand=length(input_seq); 
         
        seq_comp=zeros(1,(l_stap+l_rand-1)); 
        for i=1:(l_stap+l_rand-1) 
            b_stap1=max([(l_stap-i+1),1]); % first staple base in test range 
            b_stap2=min([l_stap,(l_rand+l_stap-i)]); % second staple base in test 
range 
            b_rand1=max([1,(i-l_stap+1)]); % first rand_seq base in test range 
            b_rand2=min([l_rand,i]); % second rand_seq base in test range 
             
            % comparing sequences 
            rand_test=input_seq(b_rand1:b_rand2); 
            stap_test=staple_Rcomp(b_stap1:b_stap2); 
            sum_seq_comp=zeros(size(rand_test)); 
             
            % calculating maximum sequential number of complementary base pairs 
            for j=1:length(rand_test) 
                if j==1 
                    if rand_test(j)==stap_test(j) 
                        sum_seq_comp(j)=1; 
                    end 
                else 
                    if rand_test(j)==stap_test(j) 
                        sum_seq_comp(j)=sum_seq_comp(j-1)+1; 
                    else 
                        sum_seq_comp(j)=0; 
                    end 
                end 
            end 
            seq_comp(i)=max(sum_seq_comp); 
%             pause(0.01) 
        end 
         
        % maximum total complementary base pairs for the staple/rand_seq combination 
        max_seq_comp1=max(seq_comp); 
        i_msc1=find(max_seq_comp1==seq_comp); 
         
        fprintf('\n\nStaple #%i: %s\nRandom sequence: 
%s\n',i_mass(nn),test_staple,input_seq) 
        for i=1:length(i_msc1) 
            b_msc_stap1=max([(l_stap-i_msc1(i)+1),1]); 
            b_msc_stap2=min([l_stap,(l_rand+l_stap-i_msc1(i))]); 
            b_msc_rand1=max([1,(i_msc1(i)-l_stap+1)]); 
            b_msc_rand2=min([l_rand,i_msc1(i)]); 
            rand_test=input_seq(b_msc_rand1:b_msc_rand2); 
            stap_test=staple_Rcomp(b_msc_stap1:b_msc_stap2); 
            n_blanks=max([l_stap,i_msc1(i)]); 
            base_match=rand_test; 
            base_match(stap_test==rand_test)='|'; 
            base_match(stap_test~=rand_test)=' '; 
            stapRC_text=strcat(sprintf(strcat('''%',num2str(i_msc1(i)),'s'''),' 
'),staple_Rcomp); 
            stap_text=strcat(sprintf(strcat('''%',num2str(i_msc1(i)),'s'''),' 
'),fliplr(test_staple)); 
            bp_text=strcat(sprintf(strcat('''%',num2str(n_blanks),'s'''),' 
'),base_match); 
            rand_text=strcat(sprintf(strcat('''%',num2str(l_stap),'s'''),' 
'),input_seq); 
            fprintf('\n%s\n%s\n%s\n%s\n',stap_text,stapRC_text,bp_text,rand_text) 
%             pause 
        end 
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    end  
%     pause(2) 
  
fprintf('\n\n****end****\n\n') 
%seq 
% overall_max_comp_consec 
  
toc 
 
 
 
